Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Emerging Biopharma
Biotech
Arch closes $3B-plus fund to foster biopharma upstarts
On the heels of Bain's $3 billion fund, Arch Venture Partners has closed a VC fund of "more than $3 billion."
Fraiser Kansteiner
Sep 26, 2024 10:24am
Flagship hopes biotechs flock to Mirai to boost genetic meds
Sep 26, 2024 6:00am
Aptadir hopes new RNA inhibitors can reverse tricky cancers
Sep 24, 2024 9:50am
New cell therapy biotech emerges from the lab of George Church
Sep 19, 2024 6:30am
AAV gene therapy biotech unveils with 10 pipeline products
Sep 12, 2024 7:00am
Candid flashes big ambitions with $370M debut
Sep 9, 2024 9:00am
More News
Medera plans SPAC merger to advance cardiac gene therapies
Sep 5, 2024 10:50am
Lilly, Haya ink $1B biobuck obesity pact to search dark genome
Sep 4, 2024 8:00am
Duality seeks cash for ADC trials as IPO wave spreads to Asia
Aug 27, 2024 9:20am
MBX files for IPO to take challenger to Ascendis into phase 3
Aug 26, 2024 9:40am
See more stories